Published in Blood on October 19, 2016
Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol (1990) 16.31
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
Plaque assay of cytomegalovirus strains of human origin. Proc Soc Exp Biol Med (1970) 5.90
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis (2002) 4.65
Genetic content of wild-type human cytomegalovirus. J Gen Virol (2004) 3.58
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet (2003) 3.55
The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol (2003) 3.48
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med (2014) 3.12
Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J Gen Virol (1989) 3.01
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother (2002) 2.98
Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature (1992) 2.98
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood (2009) 2.86
Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med (1989) 2.77
Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev (2010) 2.70
Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis (1995) 2.65
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med (2005) 2.54
Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis (1991) 2.43
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis (2011) 2.19
Ganciclovir. N Engl J Med (1996) 2.19
Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis (1997) 2.18
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis (1997) 2.14
Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci U S A (2001) 2.10
Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid. J Biol Chem (1982) 2.08
Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol (2004) 2.08
Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol (2001) 2.07
The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J Virol (1997) 2.06
Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev (1999) 2.05
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant (2003) 2.03
Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat (2002) 2.00
High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis (2002) 1.93
Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol (2009) 1.92
Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother (2005) 1.91
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev (2003) 1.91
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem (1983) 1.90
Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med (1993) 1.84
Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG). Biochem Biophys Res Commun (1982) 1.83
A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A (1986) 1.78
Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med (1988) 1.77
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis (2001) 1.77
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med (2013) 1.66
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis (2007) 1.61
Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles. J Med Chem (1995) 1.61
Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther (1986) 1.57
Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother (2009) 1.55
The antiviral activities of artemisinin and artesunate. Clin Infect Dis (2008) 1.55
Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother (1995) 1.55
Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res (2009) 1.55
Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem (1983) 1.55
Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation (2010) 1.53
Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol (1994) 1.52
Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol (2005) 1.51
Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica (2005) 1.51
Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis (1992) 1.50
Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother (1998) 1.49
Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest (1995) 1.47
Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol (1999) 1.46
Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 1.44
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med (2002) 1.39
Human cytomegalovirus genome. Curr Top Microbiol Immunol (2008) 1.37
Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis (2010) 1.37
In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother (2010) 1.36
Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother (2001) 1.36
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother (2010) 1.34
Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood (2013) 1.34
Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta (1982) 1.33
Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol (2003) 1.32
Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis (2007) 1.32
Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol (2009) 1.31
Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med (1993) 1.31
Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev Med Virol (2002) 1.31
Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood (2000) 1.30
Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet (1994) 1.29
Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis (2002) 1.28
Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol (2004) 1.27
Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol (2007) 1.27
A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother (2000) 1.27
The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol (2011) 1.25
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis (2008) 1.23
Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology (1999) 1.23
Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood (1997) 1.23
First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant (2011) 1.22
Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant (2010) 1.21
Characterization of the DNA polymerase gene of human herpesvirus 6. J Virol (1991) 1.21
How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol (2005) 1.21
Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob Agents Chemother (1999) 1.20
Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2003) 1.18
Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis (2001) 1.16
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature (1992) 1.16
Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis (1998) 1.15
Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis (1995) 1.12